VERIGENE® Bloodstream Infection Testing Panels


Rapid Detection Can Lead 
to Better Outcomes

 
Video Thumbnail
VERIGENE® System Workflow
Improves Outcomes The VERIGENE® Bloodstream Infection portfolio empowers laboratories to rapidly identify causative pathogens, as well as their associated resistance markers. Clinical studies have demonstrated that the VERIGENE Bloodstream Infection assays lower overall hospital costs, shorten the p

Outcomes Image

Improves Outcomes

The VERIGENE® Bloodstream Infection portfolio empowers laboratories to rapidly identify causative pathogens, as well as their associated resistance markers.

Clinical studies have demonstrated that the VERIGENE Bloodstream Infection assays lower overall hospital costs, shorten the patient’s length of stay, and most importantly, improve patient outcomes by enabling a more targeted treatment plan—faster.1 These assays have been proven to synergize with antimicrobial stewardship programs, reduce the use of unnecessary antibiotics, and effectively manage infection control.1,2

Panel Menu Image

Panel Menu

The VERIGENE Bloodstream Infection portfolio provides accurate test results in a clinically meaningful timeframe.

Gram-Positive Blood Culture Test (BC-GP)

Gram-Negative Blood Culture Test (BC-GN)

Species

Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus lugdunensis
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenes
Enterococcus faecalis
Enterococcus faecium

Group

Streptococcus anginosus

Genus

Staphylococcus spp.
Streptococcus spp.
Micrococcus spp.+
Listeria spp.

Resistance

mecA (methicillin)
vanA (vancomycin)
vanB (vancomycin)

Species

Escherichia coli*
Klebsiella pneumoniae
Klebsiella oxytoca
Pseudomonas aeruginosa
Serratia marcescens++

Genus

Acinetobacter spp.
Citrobacter spp.
Enterobacter spp.
Proteus spp.

Resistance

CTX-M (ESBL)
IMP (carbapenemase)
KPC (carbapenemase)
NDM (carbapenemase)
OXA (carbapenemase)
VIM (carbapenemase)

Gram-Positive Blood Culture Test (BC-GP)

Species

Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus lugdunensis
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenes
Enterococcus faecalis
Enterococcus faecium

Group

Streptococcus anginosus

Genus

Staphylococcus spp.
Streptococcus spp.
Micrococcus spp.+
Listeria spp.

Resistance

mecA (methicillin)
vanA (vancomycin)
vanB (vancomycin)

Gram-Negative Blood Culture Test (BC-GN)

Species

Escherichia coli*
Klebsiella pneumoniae
Klebsiella oxytoca
Pseudomonas aeruginosa
Serratia marcescens++

Genus

Acinetobacter spp.
Citrobacter spp.
Enterobacter spp.
Proteus spp.

Resistance

CTX-M (ESBL)
IMP (carbapenemase)
KPC (carbapenemase)
NDM (carbapenemase)
OXA (carbapenemase)
VIM (carbapenemase)

Quick Results Image

Sample to Answer

Time to results is 3x faster using the VERIGENE® System versus traditional methods.

VERIGENE Workflow Desktop Image
VERIGENE Workflow Mobile Image

Currency Image

Reduces Costs

The VERIGENE Bloodstream Infection assays enable healthcare professionals to optimize therapy earlier, which has been shown to reduce the length of inpatient care, lowering overall healthcare costs.1,2

  1. Rivard K, Athans V, Lam S, et al. Impact of antimicrobial stewardship and rapid microarray testing on patients with Gram-negative bacteremia. Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1879-87. doi: 10.1007/s10096-017-3008-6.
  2. Box M, Sullivan E, Ortwine K, et al. Outcomes of rapid identification for Gram-positive bacteremia in combination with antibiotic stewardship at a community-based hospital system. Pharmacotherapy. 2015; 35(3): 269-276.


Product Information
Peer-Reviewed Publications
Posters
Blogs
Looking for additional documentation and publications:




Video ThumbnailImproves Outcomes The VERIGENE® Bloodstream Infection portfolio empowers laboratories to rapidly identify causative pathogens, as well as their associated resistance markers. Clinical studies have demonstrated that the VERIGENE Bloodstream Infection assays lower overall hospital costs, shorten the p

Webinar: Strategic Implementation of a Rapid Molecular Blood Culture Panel for Gram Negative Bacteremia

Video ThumbnailImproves Outcomes The VERIGENE® Bloodstream Infection portfolio empowers laboratories to rapidly identify causative pathogens, as well as their associated resistance markers. Clinical studies have demonstrated that the VERIGENE Bloodstream Infection assays lower overall hospital costs, shorten the p

Webinar: Rapid Diagnostic Testing of Positive Blood Cultures & Impact on Antimicrobial Stewardship

Video ThumbnailImproves Outcomes The VERIGENE® Bloodstream Infection portfolio empowers laboratories to rapidly identify causative pathogens, as well as their associated resistance markers. Clinical studies have demonstrated that the VERIGENE Bloodstream Infection assays lower overall hospital costs, shorten the p

Webinar: The Clinical and Economic Case for Rapid Sepsis Diagnostics

Video ThumbnailImproves Outcomes The VERIGENE® Bloodstream Infection portfolio empowers laboratories to rapidly identify causative pathogens, as well as their associated resistance markers. Clinical studies have demonstrated that the VERIGENE Bloodstream Infection assays lower overall hospital costs, shorten the p

Webinar: Optimizing Therapy for Bloodstream Infections with Rapid Molecular Testing

Video ThumbnailImproves Outcomes The VERIGENE® Bloodstream Infection portfolio empowers laboratories to rapidly identify causative pathogens, as well as their associated resistance markers. Clinical studies have demonstrated that the VERIGENE Bloodstream Infection assays lower overall hospital costs, shorten the p

Webinar: Improving Management of CRE’s and Other Antibiotic-Resistant BSI’s with Rapid MDx

Video ThumbnailImproves Outcomes The VERIGENE® Bloodstream Infection portfolio empowers laboratories to rapidly identify causative pathogens, as well as their associated resistance markers. Clinical studies have demonstrated that the VERIGENE Bloodstream Infection assays lower overall hospital costs, shorten the p

Webinar: Physician and Pharmacist Perspectives on the Value of Rapid Blood Culture Testing

Video ThumbnailImproves Outcomes The VERIGENE® Bloodstream Infection portfolio empowers laboratories to rapidly identify causative pathogens, as well as their associated resistance markers. Clinical studies have demonstrated that the VERIGENE Bloodstream Infection assays lower overall hospital costs, shorten the p

Webinar: Best Practices for Multiplex Molecular Infectious Disease

 
Kit Size

Registration Status

Part Number

VERIGENE® Gram-Positive Blood Culture Test (BC-GP) Kit

20 BC-GP Test Cartridges
20 Extraction Trays

US-IVD CE Marked

20-005-018

 
VERIGENE® Gram-Positive Blood Culture Test (BC-GP) Utility Reagent Kit

20 BC-GP Utility Trays

US-IVD CE Marked

20-012-018

VERIGENE® Gram-Negative Blood Culture Nucleic Acid Test (BC-GN) Kit

20 BC-GN Test Cartridges
20 Extraction Trays

US-IVD CE Marked

20-005-021

 
VERIGENE® Gram-Negative Nucleic Acid (BC-GN) Utility Kit

20 BC-GN Utility Trays

US-IVD CE Marked

20-012-021

BC GP Test Image
VERIGENE® Gram-Positive Blood Culture Test (BC-GP) Kit

Kit Size 20 BC-GP Test Cartridges
20 Extraction Trays

Registration Status US-IVD CE Marked

Part Number 20-005-018

 
VERIGENE® Gram-Positive Blood Culture Test (BC-GP) Utility Reagent Kit

Kit Size 20 BC-GP Utility Trays

Registration Status US-IVD CE Marked

Part Number 20-012-018

BC GN Test Image
VERIGENE® Gram-Negative Blood Culture Nucleic Acid Test (BC-GN) Kit

Kit Size 20 BC-GN Test Cartridges
20 Extraction Trays

Registration Status US-IVD CE Marked

Part Number 20-005-021

 
VERIGENE® Gram-Negative Nucleic Acid (BC-GN) Utility Kit

Kit Size 20 BC-GN Utility Trays

Registration Status US-IVD CE Marked

Part Number 20-012-021

Ordering Information

Ordering information can be found here
  • Company name
  • Name, phone number, and email address of purchasing agent
  • Name and phone number of the end user
  • Valid purchase order number
  • Quote reference number, where applicable
  • Complete billing and shipping addresses
  • Product number, description, pricing, and quantity
  • Net 30 payment terms or other agreed upon payment terms
  • FOB shipping point or other agreed upon shipping terms

Video ThumbnailImproves Outcomes The VERIGENE® Bloodstream Infection portfolio empowers laboratories to rapidly identify causative pathogens, as well as their associated resistance markers. Clinical studies have demonstrated that the VERIGENE Bloodstream Infection assays lower overall hospital costs, shorten the p

Parkview Medical Center & VERIGENE® Testimonial

Video ThumbnailImproves Outcomes The VERIGENE® Bloodstream Infection portfolio empowers laboratories to rapidly identify causative pathogens, as well as their associated resistance markers. Clinical studies have demonstrated that the VERIGENE Bloodstream Infection assays lower overall hospital costs, shorten the p

Med Fusion & VERIGENE®
Testimonial

Video ThumbnailImproves Outcomes The VERIGENE® Bloodstream Infection portfolio empowers laboratories to rapidly identify causative pathogens, as well as their associated resistance markers. Clinical studies have demonstrated that the VERIGENE Bloodstream Infection assays lower overall hospital costs, shorten the p

Mission Pathogen: Luminex Virtual Reality Experience – Bloodstream Infection

For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.

Intended Use

The VERIGENE® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) performed using the sample-to-result VERIGENE System is a qualitative, multiplexed in vitro diagnostic test for the simultaneous detection and identification of potentially pathogenic gram-positive bacteria which may cause bloodstream infection (BSI). BC-GP is performed directly on blood culture bottles identified as positive by a continuous monitoring blood culture system and which contain gram-positive bacteria.

BC-GP detects and identifies the following bacterial genera and species: Staphylococcus spp., Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Streptococcus spp., Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group, Enterococcus faecalis, Enterococcus faecium, and Listeria spp.

In addition, BC-GP detects the mecA resistance marker, inferring mecA-mediated methicillin resistance, and the vanA and vanB resistance markers, inferring vanA/vanB-mediated vancomycin resistance. In mixed growth, BC-GP does not specifically attribute van-mediated vancomycin resistance to either E. faecalis or E. faecium, or mecA-mediated methicillin resistance to either S. aureusor or S. epidermidis.

BC-GP is indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial bloodstream infections; however, is not to be used to monitor these infections. Sub-culturing of positive blood cultures is necessary to recover organisms for susceptibility testing, identification of organisms not detected by BC-GP, differentiation of mixed growth, association of antimicrobial resistance marker genes to a specific organism, or for epidemiological typing.

+Micrococcus spp. is not U.S./FDA-cleared

 

The VERIGENE® Gram-Negative Blood Culture Nucleic Acid Test (BC-GN) performed using the sample-to-result VERIGENE® System is a qualitative multiplexed in vitro diagnostic test for the simultaneous detection and identification of selected gram-negative bacteria and resistance markers. BC-GN is performed directly on blood culture media using blood culture bottles identified as positive by a continuous monitoring blood culture system and which contain gram-negative bacteria as determined by Gram stain.

BC-GN detects and identifies the following Bacterial Genera and Species: Acinetobacter spp., Citrobacter spp., Enterobacter spp., Proteus spp., Escherichia coli1, Klebsiella pneumoniae, Klebsiella oxytoca, and Pseudomonas aeruginosa, and Resistance Markers: CTX-M (blaCTX-M), KPC (blaKPC), NDM (blaNDM), VIM (blaVIM), IMP (blaIMP), and OXA (blaOXA).

BC-GN is indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial bloodstream infections; however, is not used to monitor these infections. Sub-culturing of positive blood cultures is necessary to recover organisms for antimicrobial susceptibility testing (AST), for identification of organisms not detected by BC-GN, to detect mixed infections that may not be detected by BC-GN, for association of antimicrobial resistance marker genes to a specific organism, or for epidemiological typing.

* BC-GN will not distinguish Escherichia coli from Shigella spp. (S. dysenteriae, S. flexneri, S. boydii, and S. sonnei).

++Serratia marcescens is not U.S./FDA-cleared